Catalog No.
DHJ61001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Endosialin, TEM1, CD164L1, Tumor endothelial marker 1, CD248
Concentration
1.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9HCU0
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MORAb-004, CAS: 946415-62-9
Clone ID
Ontuxizumab
Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications, PMID: 26909615
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213), PMID: 29292843
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas, PMID: 31034598
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma, PMID: 29127533
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors, PMID: 30623276
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer, PMID: 29084918
CD248 as a novel therapeutic target in pulmonary arterial hypertension, PMID: 32997414
Novel antibody probes for the characterization of endosialin/TEM-1, PMID: 27494870
Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications, PMID: 26085332
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies, PMID: 33807678
Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model, PMID: 24553243
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature, PMID: 26327620
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors, PMID: 25398449
For research use only. Not for human or drug use.
